BANAMINE- flunixin meglumine paste 
Merck Sharp & Dohme Corp.

----------

Banamine®
(flunixin meglumine paste)

Paste –1500 mg
flunixin/syringe
Veterinary

For Oral Use in Horses Only

PRODUCT
INFORMATION

CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION Each 30-g syringe of BANAMINE Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS BANAMINE Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ACTIVITY Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.

CONTRAINDICATIONS There are no known contraindications to this drug when used as directed.

WARNING Do not use in horses intended for human consumption.

PRECAUTIONS The effect of BANAMINE Paste on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of BANAMINE Paste.

SIDE EFFECTS During field studies with BANAMINE Paste, no significant side effects were reported.

DOSAGE AND ADMINISTRATION The recommended dose of flunixin is 0.5 mg per lb of body weight once daily. The BANAMINE Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

DOSAGE TABLE
Syringe Mark*Horse Weight (lbs)BANAMINE Paste Delivered (g)Mg Flunixin Delivered
*
Use dial edge nearest syringe barrel to mark dose.
0
2502502.5125
5005005.0250
7507507.5375
1000100010.0500

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of BANAMINE Solution, followed by BANAMINE Granules or BANAMINE Paste on Days 2 to 5. BANAMINE treatment should not exceed 5 consecutive days.

TOXICITY No toxic effects were observed in rats given oral flunixin 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for fifteen consecutive days.

HOW SUPPLIED BANAMINE Paste, 1500 mg is available in a single 30-g syringe.

Store below 25°C (77°F). Do not Freeze.

For patent information: http://www.merck.com/product/patent/home.html

PRINCIPAL DISPLAY PANEL - 1500 mg Syringe Label

Syringe contains flunixin
meglumine equivalent to

1500 mg

FLUNIXIN
Net Wt 30 g

NDC 0061-0214-02

Banamine®
(flunixin meglumine paste)
Paste

For oral use in horses only.
Warning: Do not use in horses intended
for human consumption.
Caution: Federal law restricts this drug to
use by or on the order
of a licensed veterinarian.
Approved by FDA under NADA # 137-409

MERCK
Animal Health

PRINCIPAL DISPLAY PANEL - 1500 mg Syringe Label
BANAMINE 
flunixin meglumine paste
Product Information
Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:0061-0214
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Flunixin Meglumine (UNII: 8Y3JK0JW3U) (Flunixin - UNII:356IB1O400) Flunixin1500 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
Starch, Corn (UNII: O8232NY3SJ)  
Propylene Glycol (UNII: 6DC9Q167V3)  
Carboxymethylcellulose (UNII: 05JZI7B19X)  
Water (UNII: 059QF0KO0R)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0061-0214-0230 g in 1 SYRINGE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA13740911/11/2011
Labeler - Merck Sharp & Dohme Corp. (001317601)

Revised: 9/2019
Document Id: 89252db9-295a-479f-97e3-754977b30955
Set id: 26d5eb1e-e9f3-4c3f-abb2-fe432cf09353
Version: 4
Effective Time: 20190906
 
Merck Sharp & Dohme Corp.